Laparoscopic Power Morcellators - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The laparoscopic power morcellators market size is expected to grow from USD 130.80 million in 2025 to USD 141.73 million in 2026 and is forecast to reach USD 211.75 million by 2031 at 8.36% CAGR over 2026-2031. This report is segmented by Application (Hysterectomy, Myomectomy, and More), End User (Hospitals, Ascs, Academic Medical Centers, and Other End Users), Distribution Channel (Direct Sales, Distributors, Procurement Groups, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Laparoscopic Power Morcellators Market Trends and Insights

Adoption of Minimally Invasive Gynecological Surgery

The move from open surgery to laparoscopic treatment supports procedure volumes that use tissue extraction devices. A 2026 retrospective study found that laparoscopic myomectomy involved a 2.06-day hospital stay, compared with 2.71 days for laparotomy, and lower opioid use. These outcomes matter to hospitals because shorter stays can improve bed availability and reduce postoperative resource use. The laparoscopic power morcellators market gains a direct equipment demand link when laparoscopic myomectomy becomes the preferred pathway for eligible patients. Professional guidance issued by the European Society for Gynecological Endoscopy in 2024 supports laparoscopic abdominal myomectomy for fibroids up to 20 cm when surgeons have suitable experience. The laparoscopic power morcellators market, therefore, depends on training, operating room capacity, and surgeon confidence as much as on the number of women diagnosed with fibroids.

Persistent Burden of Uterine Fibroids and Endometriosis

Fibroids continue to create a large pool of patients who may need hysterectomy or myomectomy when symptoms cannot be managed conservatively. A 2026 study reported a global uterine-fibroid incidence rate of 250.93 per 100,000 women and an Indian rate of 326.08 per 100,000 women. The same work indicated that population growth would continue to support India’s fibroid case count through 2036. This disease burden supports the laparoscopic power morcellators market, where hospitals can provide trained minimally invasive gynecological care. It also makes the Asia-Pacific important because large case volumes can support equipment adoption once containment-compatible systems and training become available. Endometriosis remains relevant to the clinical setting, although fibroid treatment provides a more direct procedural base for tissue morcellation.

Risk of Disseminating Occult Malignancy

The possibility of spreading unsuspected uterine cancer during morcellation remains the most serious clinical barrier in the laparoscopic power morcellators market. The FDA states that unsuspected uterine sarcoma may be present in 1 in 225 to 1 in 580 women undergoing surgery for presumed fibroids. The agency also warns that power morcellation can spread cancerous tissue and reduce the likelihood of long-term survival. No preoperative test can reliably rule out uterine sarcoma in every patient with presumed fibroids, so selection decisions retain a clinical uncertainty. That uncertainty encourages hospitals and payers to limit use to carefully selected premenopausal patients. The laparoscopic power morcellators market must therefore compete with alternative surgical approaches, even when minimally invasive treatment would otherwise be preferred.

Other drivers and restraints analyzed in the detailed report include:

• Demand for Fertility-Preserving Myomectomy
• Expansion of Ambulatory Surgical Centers
• Stringent Patient-Selection and Containment Requirements

Segment Analysis

Hysterectomy accounted for 58.7% of the laparoscopic power morcellators market share in 2025, making it the largest application. The United States performs an estimated 600,000 hysterectomies each year, and the supplied research identified enlarged uteri requiring specialized extraction techniques in 30% of these procedures. The scale of this procedural base helps preserve demand for compatible tissue extraction equipment. FDA recommendations have made containment a defining element of use when power morcellation is appropriate, rather than an optional add-on.

Gynecological tissue removal is projected to grow at a 10.5% CAGR through 2031, the fastest rate among applications. The laparoscopic power morcellators market size for this application expands as tissue extraction is used in procedures outside the traditional hysterectomy and myomectomy classifications. Some of this growth reflects more specific coding of tissue-removal steps that were previously included within broader procedures. The Claria System received FDA De Novo authorization in July 2026 as an integrated gynecologic power morcellator and containment system for laparoscopic hysterectomy in selected premenopausal patients. Its authorization encourages developers to consider integrated configurations for other gynecological tissue-removal uses, while myomectomy remains supported by fertility-preservation demand.

Complete Report Scope:

• By Application
  • Hysterectomy
  • Myomectomy
  • Gynecological Tissue Removal
  • Other Applications
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Academic Medical Centers
  • Other End Users
• By Distribution Channel
  • Direct Sales
  • Medical Device Distributors
  • Hospital Procurement Groups
  • Online Medical Equipment Platforms
  • Third-Party Resellers
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.7% of the laparoscopic power morcellators market share in 2025. The region combines high gynecological procedure volumes with established laparoscopic infrastructure and regulatory requirements that influence global device design. FDA guidance requires compatible containment when laparoscopic power morcellation is appropriate, which makes product validation central to procurement. The FDA authorized the Claria System through the De Novo pathway in July 2026 and created the SIM product code for this device type. This gives hospitals a defined integrated-system option as they update legacy configurations. The growing ASC base also creates new outpatient demand, although these sites will assess device cost and workflow carefully. Canada and Mexico represent smaller opportunities shaped by public procurement and insurance arrangements.

Europe has stable demand from Germany, the United Kingdom, France, and Italy because these countries have trained specialist workforces and established hospital purchasing systems. The EU Medical Device Regulation increased post-market surveillance and evidence expectations for device suppliers. These requirements can limit smaller suppliers’ participation in tenders while rewarding firms with documented clinical and regulatory support. France’s ANSM stated in 2025 that all 14 audited operators had aligned their labeling, patient communication, and risk analysis with national recommendations. Europe consequently offers a setting where validated containment workflows may command stronger pricing than basic standalone devices.

Asia-Pacific is forecast to grow at a 9.5% CAGR through 2031, the highest regional rate. India’s fibroid incidence rate of 326.08 per 100,000 women creates a substantial potential pool of surgically eligible patients. China recorded nearly 986,000 uterine-fibroid incident cases in 2021 in the supplied research, and expanding hospital training capacity supports procedure growth. Japan remains a more mature setting for laparoscopic myomectomy, with its existing precautions emphasizing safe use. The laparoscopic power morcellators market in the region will depend on hospital investment, training, and access to compatible containment products. Middle East and Africa and South America remain smaller, with demand concentrated in GCC private healthcare systems and Brazil’s large hospital networks.

List of Companies Covered in this Report:

• Advin Health Care
• Applied Medical Resources
• B. Braun
• Blue Endo
• Boston Scientific
• BOWA Medical
• The Cooper Companies
• Conmed
• Cook Group
• Richard Wolf
• Johnson & Johnson
• Karl Storz
• LiNA Medical ApS
• Medtronic
• Microline Surgical
• Nouvag
• Olympus
• Stryker

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support